What's happening with that? And are GPs changing their practice? And what's the impact so far? And what are the frustrations and pain points around the restrictions?

Well, it's interesting because pharmacological management of obesity was very limited up until not so long ago.

We had Olistat, Zeneca, and that was all essentially.

And it was the standard diet and lifestyle, which are still important changes and things that we probably even now need to focus a little bit more on and more dedicated on, which sometimes it's tricky to.

We had Olistat, then we had nothing.

Then we had the first of the incretin therapies, which were available.

which is liraglutide, and that was three milligrams, the higher dose rather than the 1.2 to 1.8 milligrams we used in type 2 diabetes.

In your clinic, are you formally prescribing resistance training or specific protein intake targets alongside tazepatide? And how can primary care pragmatically monitor and mitigate this risk?